Variant · Fusion
FGFR1 Fusion
CI-VAR-00001365Explore in graph →CIViC 4497
Curated evidence
Evidence by cancer (4 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20594995
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| B Lymphoblastic Leukemia/Lymphoma1 | ||||||||
| BCR::FGFR1 Fusion | (oncogenic) | Oncogenic | C | Supports Oncogenicity | 2 | submitted | EID1172670 yo with t(8;22)(p11;q11) and BCR::FGFR1 rearrangement presenting as pre-B ALL with complex cytogenetic abnormalities. Flow cytometric analysis at diagnosis showed B cell immunophenotype. BCR-FGFR1 … (full text at CIViC) PMID 20594995 · Baldazzi et al., 2010 · Open in CIViC | civic |
| Lymphoid Leukemia1 | ||||||||
| ZMYM2::FGFR1 Fusion OR BCR::FGFR1 Fusion OR CEP43::FGFR1 Fusion OR TRIM24::FGFR1 Fusion OR FGFR1 Translocation | Pemigatinib | Predictive | A | Supports Sensitivity Response | 3 | submitted | EID12241In this phase 2, multicenter trial, 41 patients were enrolled who had myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements. Patients (pts) may present with… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available